Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.76 USD | +0.09% | +0.93% | -7.33% |
12:18pm | North American Morning Briefing : More Earnings -2- | DJ |
Apr. 29 | Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.31% | 3.5B | D | ||
-3.45% | 87.17B | A- | ||
+2.76% | 40.1B | A- | ||
-16.05% | 31.38B | B- | ||
+57.86% | 25.12B | A | ||
-15.94% | 15.59B | C | ||
-9.12% | 12B | D+ | ||
-42.56% | 11.8B | B | ||
-18.20% | 11.8B | B- | ||
+6.89% | 8.81B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AXSM Stock
- Ratings Axsome Therapeutics, Inc.